BioAge Labs doses first participant in Phase 2 trial
BioAge Labs announced the first participant has been dosed in QUELL-DME, a Phase 2 trial of once-daily oral BGE-102 for diabetic macular edema.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BioAge Labs doses first participant in QUELL-DME Phase 2
BioAge Labs says the first participant was dosed in QUELL-DME, a Phase 2 trial of BGE-102 in diabetic macular edema.